ClinicalTrials.gg

Program

HLX87

A development code. Also written as “HLX87 + HLX22” and “HLX87+HX22”.

In Fosun Pharma's pipeline, HER2 ADC. Its studies are mostly in Breast Neoplasms, led by Fosun Pharma.

Furthest: phase 3, since Dec 8, 20252 company-led studies, 2 open or runningNext primary completion: Jan 15, 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Fosun Pharma22 open or runningphase 3since Dec 8, 2025Dec 8, 2025Jan 15, 2028phase 3 · NCT07294508
  • Named in Fosun Pharma’s own pipeline as HLX87 (HER2 ADC), phase 3, as of Sep 21, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 8, 2025First studies: 2 phase 3 studies in Breast NeoplasmsFirst studyNCT07294534, NCT07294508

Ahead

  1. Jan 15, 2028Primary completion: phase 3 study in Breast NeoplasmsNCT07294508
  2. Sep 30, 2028Primary completion: phase 3 study in Breast NeoplasmsNCT07294534

TargetBeta

“HER2 ADC”the company's pipeline, read by Claude · source

Other programs on ERBB2

ProgramCompanyFurthest phaseStudies
TrastuzumabruleHoffmann-La Rochephase 485
pertuzumabruleHoffmann-La Rochephase 456
trastuzumab deruxtecanruleDaiichi Sankyophase 449
tucatinibrulePfizerphase 425
disitamab vedotinRemeGenphase 336
trastuzumab rezetecanruleJiangsu HengRui Medicinephase 336
Lutetium-177Novartisphase 324
trastuzumab brengitecanSichuan Biokin Pharmaceuticalphase 321
Gallium-68Philogenphase 317
zongertinibruleBoehringer Ingelheimphase 315
Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102Sino Biopharmaceuticalphase 313
sunvozertinibruleDizal Pharmaceuticalsphase 312

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07294534Breast Neoplasms3Not yet recruitingSep 30, 2028817
NCT07294508Breast Neoplasms · China3RecruitingJan 15, 2028706

How it is read

Names in the registry

  • “HLX87 + HLX22”, 1 entry
  • “HLX87+HX22”, 1 entry

Codes read as this program: HLX87.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.